Beth-Ann Coller

1.9k citations

26 papers · 1.1k indexed · h-index 17

Impact in

Infectious Diseases top 2%
- Viral Infections and Vectors
- Viral Infections and Outbreaks Research
- SARS-CoV-2 and COVID-19 Research
- Viral gastroenteritis research and epidemiology
Public Health, Environmental and Occupational Health top 2%
- Mosquito-borne diseases and control
- Malaria Research and Control

Papers in ⓘ

Infectious Diseases 22
- Viral Infections and Vectors 19
- Viral Infections and Outbreaks Research 18
- SARS-CoV-2 and COVID-19 Research 4
Public Health, Environmental and Occupational Health 10
- Mosquito-borne diseases and control 10
- Malaria Research and Control 4

Co-authors: David E. Clements (6 shared papers)Andrew J. Bett (3 shared papers)Jan H. ter Meulen (2 shared papers)Sheri Dubey (12 shared papers)Sangeetha L. Sagar (1 shared paper)Jakub K. Simon (8 shared papers)J. Robert Putnak (2 shared papers)Gary S. Bignami (2 shared papers)
Journals: Vaccine (9 papers)Vaccines (3 papers)Human Vaccines & Immunotherapeutics (2 papers)Current Opinion in Immunology (1 paper)Journal of Wildlife Diseases (1 paper)
Partner nations: United States Thailand Australia

In The Last Decade

Beth-Ann Coller

25 papers receiving 1.1k citations

Peers

Countries citing papers authored by Beth-Ann Coller

Since Specialization

Citations

This map shows the geographic impact of Beth-Ann Coller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth-Ann Coller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth-Ann Coller more than expected).

Fields of papers citing papers by Beth-Ann Coller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth-Ann Coller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth-Ann Coller. The network helps show where Beth-Ann Coller may publish in the future.

Co-authors

The 25 scholars most cited alongside Beth-Ann Coller, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Beth-Ann Coller Line = papers co-authored together Beth-Ann Coller links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys Vaccine ·David E. Clements, Beth-Ann Coller, Michael M. Lieberman, Steven Ogata, Gordon Wang, Kent E. Harada, J. Robert Putnak, John M. Ivy, Michael McDonell, Gary S. Bignami, Iain D. Peters, Julia P. Leung, Carolyn Weeks-Levy, Eileen Nakano, Tom Humphreys	2010	160
2	An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model Vaccine ·J. Robert Putnak, Beth-Ann Coller, Gérald Voss, David W. Vaughn, David E. Clements, Iain D. Peters, Gary S. Bignami, Hou-Shu Houng, Robert C.-M. Chen, David A. Barvir, J Seriwatana, Sylvie Cayphas, Nathalie Garçon, Dirk Gheysen, Niranjan Kanesa-thasan, Mike McDonell, Tom Humphreys, Kenneth H. Eckels, Jean‐Paul Prieels, Bruce L. Innis	2005	130
3	The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease Vaccine ·Beth-Ann Coller, David E. Clements, Andrew J. Bett, Sangeetha L. Sagar, Jan H. ter Meulen	2011	116
4	Dengue vaccines: progress and challenges Current Opinion in Immunology ·Beth-Ann Coller, David E. Clements	2011	101
5	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants Vaccine ·David Greenberg, Patricia Hoover, Timo Vesikari, Christopher B. Peltier, David Hurley, Richard McFetridge, Michael J. Dallas, Jonathan Hartzel, Rocio D. Marchese, Beth-Ann Coller, Jon E. Stek, Chitrananda Abeygunawardana, Michael A. Winters, John E. MacNair, Narahari S. Pujar, Luwy Musey	2018	78
6	rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment Vaccine X ·Thomas P. Monath, Patricia Fast, Kayvon Modjarrad, David K. Clarke, Brian K. Martin, Joan Fusco, Richard Nichols, D. Gray Heppner, Jakub K. Simon, Sheri Dubey, Sean P. Troth, Jayanthi Wolf, Vidisha Singh, Beth-Ann Coller, James S. Robertson	2019	61
7	Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates Vaccine ·Dhanasekaran Govindarajan, Steven Meschino, Liming Guan, David E. Clements, Jan H. ter Meulen, Danilo R. Casimiro, Beth-Ann Coller, Andrew J. Bett	2015	59
8	Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults Human Vaccines & Immunotherapeutics ·Susan B. Manoff, Michele Sausser, Amy Falk Russell, Jason Martin, David Radley, Donna Hyatt, Christine C. Roberts, Jason D. Lickliter, Janakan Krishnarajah, Andrew Bett, Sheri Dubey, Tyler S. Finn, Beth-Ann Coller	2018	52
9	Preclinical and clinical development of a dengue recombinant subunit vaccine Vaccine ·Susan B. Manoff, Sarah L. George, Andrew J. Bett, Michele L. Yelmene, Dhanasekaran Govindarajan, Linda M. Eggemeyer, Michele Sausser, Sheri Dubey, Danilo R. Casimiro, David E. Clements, Timothy Martyak, Vidya Pai, D E Parks, Beth-Ann Coller	2015	51
10	Development of Pandemic Vaccines: ERVEBO Case Study Vaccines ·Jayanthi Wolf, Risat Jannat, Sheri Dubey, Sean P. Troth, Matthew Onorato, Beth-Ann Coller, Mary E. Hanson, Jakub K. Simon	2021	40
11	Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens npj Vaccines ·Jayanthi Wolf, Samantha Bruno, M.J. Eichberg, Risat Jannat, Sharon Rudo, Susan M. VanRheenen, Beth-Ann Coller	2020	37
12	Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic Vaccine ·Beth-Ann Coller, Jeffrey T. Blue, Rituparna Das, Sheri Dubey, L. Finelli, Swati Gupta, F.A. Helmond, Rebecca J. Grant-Klein, Kenneth Liu, Jakub K. Simon, Sean P. Troth, Susan M. VanRheenen, Julie A. Waterbury, Ashley Wivel, Jayanthi Wolf, D. Gray Heppner, Tracy Kemp, Richard Nichols, Thomas P. Monath	2017	35
13	Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults The Journal of Infectious Diseases ·Scott A. Halperin, Rituparna Das, Matthew Onorato, Kenneth Liu, Jason Martin, Rebecca J. Grant-Klein, Richard Nichols, Beth-Ann Coller, F.A. Helmond, Jakub K. Simon	2019	34
14	Advances in the understanding, management, and prevention of dengue Journal of Clinical Virology ·Laura L. Hermann, Swati Gupta, Susan B. Manoff, Siripen Kalayanarooj, Robert V. Gibbons, Beth-Ann Coller	2014	33
15	Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines Vaccine ·Heng Liu, Laura Bungener, Wouter ter Veer, Beth-Ann Coller, Jan Wilschut, Anke Huckriede	2011	21
16	A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults Human Vaccines & Immunotherapeutics ·Kevin L. Russell, Richard Rupp, Javier O Morales-Ramirez, Clemente Díaz-Pérez, Charles P. Andrews, Andrew W. Lee, Tyler S. Finn, Kara S. Cox, Amy Falk Russell, Margaret M. Schaller, Jason Martin, Donna Hyatt, Sabrina Gozlan-Kelner, Androniki Bili, Beth-Ann Coller	2022	20
17	Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials The Lancet Microbe ·Rebecca F. Grais, Stephen B. Kennedy, Barbara E. Mahon, Sheri Dubey, Rebecca J. Grant-Klein, Ken Liu, Jonathan Hartzel, Beth-Ann Coller, Carolee Welebob, Mary E. Hanson, Jakub K. Simon	2021	17
18	Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates Cell Reports ·Bronwyn M. Gunn, Ryan P. McNamara, Lianna Wood, Sabian Taylor, Anush Devadhasan, Wenyu Guo, Jishnu Das, Avlant Nilsson, Amy C. Shurtleff, Sheri Dubey, M.J. Eichberg, Todd J. Suscovich, Erica Ollmann Saphire, Douglas A. Lauffenburger, Beth-Ann Coller, Jakub K. Simon, Galit Alter	2023	12
19	Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials Vaccine ·Jakub K. Simon, Stephen B. Kennedy, Barbara E. Mahon, Sheri Dubey, Rebecca J. Grant-Klein, Ken Liu, Jonathan Hartzel, Beth-Ann Coller, Carolee Welebob, Mary E. Hanson, Rebecca F. Grais	2022	11
20	Vaccination of Captive Nēnē (Branta sandvicensis) against West Nile Virus Using a Protein-based Vaccine (WN-80E) Journal of Wildlife Diseases ·Susan I. Jarvi, Darcy Hu, Kathleen Misajon, Beth-Ann Coller, Teri Ann S. Wong, Michael M. Lieberman	2013	9

About Beth-Ann Coller

Beth-Ann Coller is a scholar working on Infectious Diseases, Public Health, Environmental and Occupational Health, Epidemiology, Sociology and Political Science and Modeling and Simulation, having authored 26 papers that have together received 1.1k indexed citations. Recurring topics across this work include Viral Infections and Vectors (19 papers), Viral Infections and Outbreaks Research (18 papers), Mosquito-borne diseases and control (10 papers), Malaria Research and Control (4 papers), SARS-CoV-2 and COVID-19 Research (4 papers), Virology and Viral Diseases (4 papers), COVID-19 epidemiological studies (3 papers) and Global Security and Public Health (3 papers). The work is most often cited by research in Infectious Diseases (771 citations), Public Health, Environmental and Occupational Health (668 citations), Modeling and Simulation (56 citations), Virology (42 citations) and Microbiology (45 citations). Beth-Ann Coller has collaborated with scholars based in United States, Thailand and Australia. Frequent co-authors include David E. Clements, Andrew J. Bett, Jan H. ter Meulen, Sheri Dubey, Sangeetha L. Sagar, Jakub K. Simon, J. Robert Putnak, Gary S. Bignami, Jayanthi Wolf and Tom Humphreys. Their work appears in journals such as Vaccine, Vaccines, Human Vaccines & Immunotherapeutics, Current Opinion in Immunology and Journal of Wildlife Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact